Search
SOLACI Congress
HomeFilePharmacology

Pharmacology

View Category

Acute coronary syndromes

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the...
Dr. Andrés Rodríguez -
Learn More
Antithrombotic Anticoagulants

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series....
Dr. Carlos Fava -
Learn More
Antiplatelet

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which...
Dr. Andrés Rodríguez -
Learn More
Antithrombotic Anticoagulants

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral...
Dr. Carlos Fava -
Learn More
Acute coronary syndromes

ESC 2024 | SCOFF Trial: Fasting or No Fasting before Cardiac Catheterization Procedures

Millions of people undergo either diagnostic or therapeutic coronary procedures that require sedation. The aim of this...
Dr. Omar Tupayachi -
Learn More
Antithrombotic Anticoagulants

ESC 2024 | POPular PAUSE TAVI: Continuation vs. Discontinuation of Oral Anticoagulant Therapy During TAVI

Due to their advanced age and comorbidities, many patients with severe aortic stenosis scheduled for transcatheter aortic...
Dr. Omar Tupayachi -
Learn More
Antiplatelet

ESC 2024 | QUADRO Trial: Efficacy and Safety of the First Quadruple Therapy Single Pill in Resistant Hypertension Patients

Researchers conducted an international, randomized, parallel-group study with a superiority design over a 16-week period. The doses...
Dr. Omar Tupayachi -
Learn More
Acute coronary syndromes

ESC 2024 | AßYSS: Discontinuation of Beta-Blocker Treatment After One Year in Uncomplicated MI

Researchers presented a non-inferiority study conducted at 49 centers in France, with a randomized cohort of stable post-acute...
Dr. Omar Tupayachi -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Dr. Andrés Rodríguez - 0
Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Dr. Omar Tupayachi - 0
Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Dr. Omar Tupayachi - 0
Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Institutional News

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy